00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
17:22 , Mar 22, 2019 |  BC Week In Review  |  Company News

Petra gains Takeda's PI3K inhibitor pipeline

Takeda granted Petra a license to develop, manufacture and commercialize serabelisib (TAK-117) and additional PI3Kα inhibitors. Petra Pharma Corp. (New York, N.Y.) has rights to the inhibitors in all indications except for a set of...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
17:05 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Verastem raises $150M in notes offering

Verastem Inc. (NASDAQ:VSTM) raised $150 million on Oct. 11 through the sale of 5% convertible senior notes due 2048. The notes have an initial conversion price of about $7.16, which is a 14% premium to...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
17:38 , Sep 28, 2018 |  BC Week In Review  |  Company News

Verastem grants CSPC rights to Copiktra in China

Verastem Inc. (NASDAQ:VSTM) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights to develop and commercialize cancer drug Copiktra duvelisib in China, including Hong Kong and Macau, and Taiwan. The partners announced the deal on Sept....
17:37 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

FDA approves Verastem's duvelisib

FDA approved Copiktra duvelisib from Verastem Inc. (NASDAQ:VSTM) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. The agency also granted accelerated approval to...
22:43 , Sep 25, 2018 |  BC Extra  |  Company News

Verastem grants CSPC rights to Copiktra in China

Verastem Inc. (NASDAQ:VSTM) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights to develop and commercialize cancer drug Copiktra duvelisib in China, including Hong Kong and Macau, and Taiwan. On Monday, Copiktra became the first dual...
22:21 , Sep 24, 2018 |  BC Extra  |  Company News

FDA approves Verastem's duvelisib

FDA approved Copiktra duvelisib from Verastem Inc. (NASDAQ:VSTM) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. The agency also granted accelerated approval to...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...